Literature DB >> 23305866

Red blood cells as innovative antigen carrier to induce specific immune tolerance.

Magali Cremel1, Nathalie Guérin, Françoise Horand, Alice Banz, Yann Godfrin.   

Abstract

The route of administration, the dose of antigen as well as the type of antigen-presenting cells (APCs) targeted are important factors to induce immune tolerance. Despite encouraging results obtained in animal models, intravenous injection of soluble antigen is unsuccessful in human clinical trials on autoimmune disease due to inefficient antigen delivery. To improve antigen delivery, we used mouse red blood cells (RBCs) as antigen vehicles to specifically target APCs which are responsible for removal of senescent RBCs after phagocytosis. In this study, we demonstrated that antigen-delivery by RBCs induced a strong decrease in the humoral response compared with the ovalbumin (OVA) free form in mice. In addition, OVA-loaded RBC treated with [bis(sulphosuccinimidyl)] suberate (BS3), a chemical compound known to enhance RBC phagocytosis, induced an inhibition of antigen-specific T cell responses and an increase in the percentage of regulatory T cells. The state of tolerance induced is long lasting, antigen-specific and sufficiently robust to withstand immunization with antigen mixed with cholera toxin adjuvant. This RBC strategy, which does not abolish the immune system, constitutes an attractive approach for induction of tolerance compared to systemic immunosuppressant therapies already in use.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23305866     DOI: 10.1016/j.ijpharm.2012.12.044

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  27 in total

1.  Syngeneic red blood cell-induced extracellular vesicles suppress delayed-type hypersensitivity to self-antigens in mice.

Authors:  Katarzyna Nazimek; Eugenio Bustos-Morán; Noelia Blas-Rus; Bernadeta Nowak; Włodzimierz Ptak; Philip W Askenase; Francisco Sánchez-Madrid; Krzysztof Bryniarski
Journal:  Clin Exp Allergy       Date:  2019-08-26       Impact factor: 5.018

Review 2.  Nanocarrier fabrication and macromolecule drug delivery: challenges and opportunities.

Authors:  Vibhuti Agrahari; Vivek Agrahari; Ashim K Mitra
Journal:  Ther Deliv       Date:  2016

Review 3.  Bioconjugate Strategies for the Induction of Antigen-Specific Tolerance in Autoimmune Diseases.

Authors:  Chunsong Yu; Jingchao Xi; Meng Li; Myunggi An; Haipeng Liu
Journal:  Bioconjug Chem       Date:  2017-12-06       Impact factor: 4.774

4.  Murine Red Blood Cells Lack Ligands for B Cell Siglecs, Allowing Strong Activation by Erythrocyte Surface Antigens.

Authors:  Fernando Spiller; Corwin M Nycholat; Chika Kikuchi; James C Paulson; Matthew S Macauley
Journal:  J Immunol       Date:  2017-12-29       Impact factor: 5.422

Review 5.  Biologia Futura: Emerging antigen-specific therapies for autoimmune diseases.

Authors:  Gabriella Sármay
Journal:  Biol Futur       Date:  2021-02-04

Review 6.  Cell-penetrating peptides meditated encapsulation of protein therapeutics into intact red blood cells and its application.

Authors:  Huining He; Junxiao Ye; Yinsong Wang; Quan Liu; Hee Sun Chung; Young Min Kwon; Meong Cheol Shin; Kyuri Lee; Victor C Yang
Journal:  J Control Release       Date:  2013-12-27       Impact factor: 9.776

Review 7.  Factors Influencing RBC Alloimmunization: Lessons Learned from Murine Models.

Authors:  Alex B Ryder; James C Zimring; Jeanne E Hendrickson
Journal:  Transfus Med Hemother       Date:  2014-11-17       Impact factor: 3.747

8.  Engineered erythrocytes covalently linked to antigenic peptides can protect against autoimmune disease.

Authors:  Novalia Pishesha; Angelina M Bilate; Marsha C Wibowo; Nai-Jia Huang; Zeyang Li; Rhogerry Deshycka; Djenet Bousbaine; Hojun Li; Heide C Patterson; Stephanie K Dougan; Takeshi Maruyama; Harvey F Lodish; Hidde L Ploegh
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-07       Impact factor: 12.779

Review 9.  Cell or cell membrane-based drug delivery systems.

Authors:  Songwei Tan; Tingting Wu; Dan Zhang; Zhiping Zhang
Journal:  Theranostics       Date:  2015-04-27       Impact factor: 11.556

10.  Expansion of immature, nucleated red blood cells by transient low-dose methotrexate immune tolerance induction in mice.

Authors:  J Q Tran; D Grover; M Zhang; M Stapels; R Brennan; D S Bangari; P A Piepenhagen; E Roberts; P Oliva; F Zubair; J L Vela; S M Richards; A M Joseph
Journal:  Clin Exp Immunol       Date:  2020-12-16       Impact factor: 5.732

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.